Search

Your search keyword '"Gale, Richard"' showing total 1,173 results

Search Constraints

Start Over You searched for: Author "Gale, Richard" Remove constraint Author: "Gale, Richard"
1,173 results on '"Gale, Richard"'

Search Results

3. The UK clinical eye research strategy: refreshing research priorities for clinical eye research in the UK

4. Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3

6. Associations of presenting visual acuity with morphological changes on OCT in neovascular age-related macular degeneration: PRECISE Study Report 2

9. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

12. Improved Structure and Function in Early-Detected Second-Eye Neovascular Age-Related Macular Degeneration: FASBAT/Early Detection of Neovascular Age-Related Macular Degeneration Report 1

15. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

17. Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus

18. The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus

20. Subretinal transient hyporeflectivity in neovascular age-related macular degeneration and its response to a loading phase of aflibercept: PRECISE report 4

23. Improved structure and function in early detected second eye neovascular age-related macular degeneration; FASBAT/EDNA report 1

26. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

27. Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis.

28. Energy Medicine, the New Paradigm to Displace the Medical Establishment

30. TENAYA and LUCERNE

31. Treatment of age‐related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4‐year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial).

32. Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3

33. Associations of presenting visual acuity with morphological changes on OCT in neovascular age-related macular degeneration: PRECISE Study Report 2

37. Quantitative assessment of the outcome of anti-vascular endothelial growth factor treatment for neovascular macular degeneration

38. Wikipedia's Skeptical Assault on Botanical Medicine

40. Sink or SWMM: Simulating the Hydrological Effects of Retention Tanks in a Small Urban Catchment

41. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study

42. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study

43. Treatment of age‐related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4‐year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial)

Catalog

Books, media, physical & digital resources